Department of Cardiothoracic Surgery, Xiangya Second Hospital, Central South University, Changsha, Hunan 410011, China.
Stem Cell Rev Rep. 2011 Mar;7(1):172-80. doi: 10.1007/s12015-010-9131-8.
Myocardial infarction (MI) remains a common fatal disease all over the world. The adult cardiac myocytes regenerative capability is very limited after infarct injury. Heart transplantation would be the best therapeutic option currently but is restricted due to the lack of donor organs and the serious side effects of immune suppression. The emerging of tissue engineering has evolved to provide solutions to tissue repair and replacement. Engineering myocardial tissue is considered to be a new therapeutic approach to repair infarcted myocardium and ameliorate cardiac function after MI. Engineering myocardial tissue is the combination of biodegradable scaffolds with viable cells and has made much progress in the experimental phase. However, the largest challenge of this field is the revascularization of the engineering constructs to provide oxygen and nutrients for cells. This review will give an overview on the current evolution of engineering myocardial tissue and address a new method to improve the vascularization of myocardium tissue in vivo.
心肌梗死（MI）仍然是全世界常见的致命疾病。成人心肌细胞在梗塞损伤后再生能力非常有限。心脏移植目前是最好的治疗选择，但由于供体器官缺乏和免疫抑制的严重副作用而受到限制。组织工程学的出现为组织修复和替代提供了解决方案。工程化心肌组织被认为是修复梗死心肌和改善心肌梗死后心功能的一种新的治疗方法。工程化心肌组织是将生物可降解支架与有活力的细胞相结合的产物，在实验阶段已经取得了很大的进展。然而，该领域最大的挑战是工程化构建物的再血管化，以提供细胞所需的氧气和营养物质。本文综述了工程化心肌组织的最新进展，并提出了一种改善体内心肌组织血管化的新方法。
